STANDARD BIOTOOLS (NASDAQ: LAB) director awarded RSUs and stock options in new Form 4

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. director Eloi Fenel M reported equity awards consisting of restricted stock units and stock options. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027 or one day before the next annual stockholders’ meeting, contingent on continued service. Each RSU converts into one common share at vesting, bringing direct common stock holdings to 335,299 shares after the award. He was also granted a stock option for 175,923 shares at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning July 18, 2026 and expiring on June 18, 2036.

Insights

Equity compensation analyst

Director received routine RSU and option grants, increasing long-term equity exposure.

The filing shows Eloi Fenel M, a director of STANDARD BIOTOOLS INC., receiving equity compensation rather than trading in the open market. The awards include 99,116 RSUs and options for 175,923 shares at $0.8297 per share.

The RSUs cliff-vest on the earlier of June 18, 2027 or one day before the next annual stockholders’ meeting, subject to continued service. The options vest monthly over a year starting July 18, 2026 and expire on June 18, 2036, creating a staggered vesting schedule tied to ongoing board service.

This pattern is consistent with standard director compensation, with no buys or sells reported. Actual dilution impact and future cash flows depend on how many RSUs vest and whether the options are ultimately exercised at or above the $0.8297 strike price.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider ELOI FENEL M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	175,923	$0.00	--
Grant/Award	Common Stock	99,116	$0.00	--

Holdings After Transaction: Stock Option (Right to buy) — 175,923 shares (Direct, null); Common Stock — 335,299 shares (Direct, null)

Footnotes (1)

1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

RSU grant size: 99,116 shares Common shares after grant: 335,299 shares Option grant size: 175,923 shares +4 more

7 metrics

RSU grant size 99,116 shares Restricted Stock Units granted on June 18, 2026

Common shares after grant 335,299 shares Director’s direct common stock holdings following RSU award

Option grant size 175,923 shares Stock option covering common stock granted on June 18, 2026

Option exercise price $0.8297 per share Strike price for the 175,923-share stock option grant

RSU vesting date June 18, 2027 (or earlier alternative date) RSUs vest on earlier of June 18, 2027 or one day before next annual meeting

Option vesting start July 18, 2026 Options vest in 12 equal monthly installments beginning this date

Option expiration June 18, 2036 Expiration date of the stock option grant

Key Terms

Restricted Stock Units ("RSUs"), Stock Option (Right to buy), vest in full, exercise price, +1 more

5 terms

Restricted Stock Units ("RSUs") financial

"Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to buy) financial

"Stock Option (Right to buy) with an exercise price of 0.8297 and expiration date of June 18, 2036..."

vest in full financial

"RSUs that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date..."

exercise price financial

"conversion_or_exercise_price of 0.8297 for the Stock Option (Right to buy)..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

twelve equal monthly installments financial

"The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026..."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ELOI FENEL M

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

50 MILK STREET, 10TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		A		99,116(1)	A	$0	335,299	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$0.8297	06/18/2026		A		175,923		(2)	06/18/2036	Common Stock	175,923	$0	175,923	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

2. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Fenel M. Eloi by Tomone Tanaka, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did director Eloi Fenel M receive from STANDARD BIOTOOLS INC. (LAB)?

Eloi Fenel M received 99,116 RSUs and options for 175,923 shares. The RSUs convert into common stock upon vesting, and the options have a strike price of $0.8297 per share, providing additional potential future ownership if exercised.

When do the new RSUs for STANDARD BIOTOOLS INC. (LAB) director vest?

The 99,116 RSUs vest in full on a single future date. They vest on the earlier of June 18, 2027, or one day before the company’s next annual stockholders’ meeting, assuming the director continues to serve through the applicable vesting date.

What are the key terms of the new stock options granted to the LAB director?

The director received options for 175,923 shares at $0.8297 per share. These options vest in twelve equal monthly installments starting July 18, 2026, and remain exercisable until their expiration on June 18, 2036, subject to continued service.

How many STANDARD BIOTOOLS INC. shares does the director hold after these awards?

After the RSU grant, the director directly holds 335,299 common shares. This figure reflects his updated non-derivative ownership position and excludes the 175,923 shares underlying the newly granted stock options, which are separate derivative securities.

Does this STANDARD BIOTOOLS INC. Form 4 show any open-market buys or sells by the director?

The Form 4 reports only equity awards, not market trades. Both transactions are coded as grants or awards, representing RSUs and stock options provided as compensation, with no reported open-market purchases or sales of LAB common stock.